When a patient with chronic lymphocytic leukaemia (CLL) has experienced intolerance to ibrutinib, a distinct therapeutic path is indicated. The appropriate next step depends on the specific nature of the intolerance encountered.
This protocol addresses patients with CLL who have a documented history of ibrutinib intolerance. Not all intolerances are equivalent — the type of adverse effect or toxicity drives the selection of alternative therapy.
Venetoclax-based therapy is among the evidence-based options considered in this setting. The nature of the prior intolerance determines whether this or an alternative targeted approach is most appropriate.
Full option set, decision algorithm, and regimen details available in the complete protocol below.